Structure via PubChem · Public domain (PubChem)
pemigatinib
Sign in to savePemigatinib, sold under the brand name Pemazyre, is an anti-cancer medication used for the treatment of bile duct cancer (cholangiocarcinoma). Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading.
Chemical data
- Formula
- C24H27F2N5O4
- Molecular weight
- 487.5 g/mol
- IUPAC name
- 11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one
- SMILES
- CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5
- InChIKey
- HCDMJFOHIXMBOV-UHFFFAOYSA-N
- XLogP
- 1.8
- Polar surface area
- 83.2 Ų
- H-bond donors
- 1
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 487.2031107840001
- Has use
- medication
Show 4 more facts
- chemical formula
- C₂₄H₂₇F₂N₅O₄
- canonical SMILES
- CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21
- subject has role
- protein kinase inhibitors
- medical condition treated
- cholangiocarcinoma
via Wikidata · CC0
~6 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- History
- Society and culture
- Names
- References
- Further reading
- External links
Pemigatinib, sold under the brand name Pemazyre, is an anti-cancer medication used for the treatment of bile duct cancer (cholangiocarcinoma). Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading.
Pemigatinib belongs to a group of medicines called protein kinase inhibitors. It works by blocking enzymes known as protein kinases, particularly those that are part of receptors (targets) called fibroblast growth factor receptors (FGFRs). FGFRs are found on the surface of cancer cells and are involved in the growth and spread of the cancer cells. By blocking the tyrosine kinases in FGFRs, pemigatinib is expected to reduce the growth and spread of the cancer.
Excerpted from Wikipedia’s “pemigatinib” article, available under the CC BY-SA 4.0 licence.